Search For a Provider Facebook Twitter Instagram YouTube ES View the Patient Toolkit


Study: ED Drugs Don’t Increase Risk for Prostate Cancer Recurrence

Feb 03, 2016

Two hundred ninety-three men had biochemical recurrence after treatment with radical prostatectomy (surgical removal of the prostate gland) and radiation therapy. The researchers then gathered information from 5,767 men who did not have biochemical recurrence and compared the two groups.

PDE5 inhibitors were used by 51% of the men who experienced biochemical recurrence. Among men who didn’t have a recurrence, 58% used these medications.

They research team found that using PDE5 inhibitors was not associated with biochemical recurrence for either type of treatment. Even after accounting for factors like marital status, education, income, PSA levels, and stage of cancer, there was still no connection.

The authors concluded that doctors do not need to change their approach to treating ED after prostate cancer treatment.

The study was published online in December in the journal European Urology.

Print this article or view it as a PDF file here: Study: ED Drugs Don’t Increase Risk for Prostate Cancer Recurrence


European Urology

Loeb, Stacy, et al.

“Phosphodiesterase Type 5 Inhibitor Use and Disease Recurrence After Prostate Cancer Treatment”

(Abstract. Published online: December 30, 2015)

National Cancer Institute

“Biochemical Recurrence”

“Prostate-Specific Antigen (PSA) Test”

(Reviewed: July 24, 2012)

Renal and Urology News

Charnow, Jody A.

“Erectile Dysfunction Drugs Do Not Affect Prostate Cancer Relapse Risk”

(January 5, 2016)

Reuters Health via Journal of Clinical Pathways

Boggs, Will, MD

“Erectile dysfunction meds don't boost prostate cancer recurrence”

(January 13, 2016)

« Previous 1 2 (page 2 of 2)